Hardie Robert D.'s Form 4 filing
Acumen Pharmaceuticals, Inc. (ABOS) · filed Jul 8, 2021
- Accession no.
- 0001209191-21-046028
- Filed
- Jul 8, 2021
- Trade date
- Jul 6, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 3 derivative transactions. Open-market purchases total $5.00M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hardie Robert D.CIK 0001804350 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 6, 2021 | Common Stock | CConversionAcquired | +2,950,484 | –F1 | – | 3,040,193 | Indirect | |
| Jul 6, 2021 | Common Stock | PPurchaseAcquired | +312,500 | $16.00 | +$5,000,000 | 3,352,693 | Indirect | |
| Jul 6, 2021 | Common Stock | CConversionAcquired | +657,985 | –F1 | – | 657,985 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 6, 2021 | Common Stock | CConversionDisposed | −1,634,515 | $0.00 | $0 | 0 | Indirect | |
| Jul 6, 2021 | Common Stock | CConversionDisposed | −1,315,969 | $0.00 | $0 | 0 | Indirect | |
| Jul 6, 2021 | Common Stock | CConversionDisposed | −657,985 | $0.00 | $0 | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
Referenced by the price of 2 transactions in Table I.